Gilead Sciences, Inc. (GILD)
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
Gilead Sciences (GILD) Rises Yet Lags Behind Market: Some Facts Worth Knowing
In the latest trading session, Gilead Sciences (GILD) closed at $92.38, marking a +1.52% move from the previous day.
Gilead Sciences, US government settle patent case over HIV prevention drugs
Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to a Wednesday filing in Delaware federal court.
Gilead Sciences, Inc. (GILD) JPMorgan Annual Healthcare Conference - (Transcript)
Gilead Sciences, Inc. (NASDAQ:GILD ) JPMorgan Annual Healthcare Conference Call January 13, 2025 2:15 PM ET Company Participants Daniel O'Day - Chairman and Chief Executive Officer Johanna Mercier - Chief Commercial Officer Stacey Ma - Executive Vice President, Pharmaceutical Development and Manufacturing Andrew Dickinson - Chief Financial Officer Flavius Martin - Executive Vice President, Research Conference Call Participants Chris Schott - JPMorgan Chris Schott Good morning, everybody. I'm Chris Schott from JPMorgan and it's my pleasure to be introducing Gilead today.
Gilead CEO on funding for new HIV prevention medicine
CNBC's Angelica Peebles and Gilead chairman and CEO Daniel O'Day join ‘Squawk Box' to discuss the company's new HIV prevention medicine, impact of the incoming Trump administration on health care, and more.
Gilead CEO Daniel O'Day on new HIV prevention medicine: It's going to change the face of HIV
CNBC's Angelica Peebles and Gilead chairman and CEO Daniel O'Day join 'Squawk Box' to discuss the company's new HIV prevention medicine, impact of the incoming Trump administration on health care, and more.
Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know
In the latest trading session, Gilead Sciences (GILD) closed at $89.14, marking a -1.64% move from the previous day.
Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for Investors
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $91.41, denoting a -0.51% change from the preceding trading day.
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
Gilead Stock Gains 15.4% in a Year: Should You Buy, Sell or Hold?
GILD has put up a steady performance in 2024, with a new drug approval, positive data readouts and strong quarterly results. We believe there is more room for growth, given GILD's strong fundamentals.
GILD's Trodelvy Gets Second Breakthrough Therapy Tag for Lung Cancer
Gilead announces that the FDA grants a second Breakthrough Therapy designation to Trodelvy for the extensive-stage small cell lung cancer indication.
5 High Earnings Yield Value Picks to Buy for 2025
Unlock your portfolio value with these high earnings yield value stocks, PBI, GPOR, KINS, NATL and GILD.
